www.hivandhepatitis.com

BHIVA 2015: Undiagnosed HIV Infections Picked Up When Testing People with Other Medical Conditions

A Europe-wide project offering HIV tests to hospital patients with glandular fever symptoms, swollen lymph nodes, a low white blood cell count, a low platelet count, or pneumonia has found that over 3% of tested patients had previously undiagnosed HIV, according to a presentation at the British HIV Association (BHIVA) annual meeting last month in Brighton. This significantly exceeds the level of 0.1% HIV prevalence at which routine HIV testing interventions are considered to be cost-effective. 

[Produced in collaboration with Aidsmap.com]

The study results show the importance of getting non-HIV specialist clinicians to consider HIV testing for patients with a wide range of illnesses that might be indicative of HIV infection. However this remains challenging.

Since 2007, specialist HIV clinicians in Europe have been attempting to encourage other doctors to offer HIV tests to patients with specific "indicator conditions." An indicator condition is one that is known or believed to be associated with an excess risk of being HIV-positive. For example, some of these conditions are sometimes caused by having a weakened immune system, while viral hepatitis is transmitted in similar ways to HIV. Guidance on testing people with indicator conditions was published in 2012. In contrast, theU.S. Preventive Services Task Force recommends that all adolescents and adults ages 15 through 65 years should receive routine HIV screening as part of their normal medical care.

The new research builds on earlier studies in order to clarify which medical conditions are associated with higher than average HIV rates. At 42 clinics in 20 European countries, doctors were asked to routinely offer an HIV test to all patients (aged 18 to 65) who presented with one of 14 indicator conditions.

In total, 9741 people took an HIV test, most of them for the first time in their life. Among those testing, the overall prevalence of undiagnosed HIV infection was very high at 2.5%. Further, 7 in 10 of those testing positive were diagnosed late (CD4 count below 350 cells/mm³) and half were diagnosed very late (below 200 cells/mm³).

Routine HIV testing is thought to be cost-effective in any population where the prevalence of HIV is 0.1% or above. In this study, overall prevalence in people with one of the indicator conditions was 25 times greater than that. Moreover, it was over 0.1% for 11 of the 14 conditions tested:

• Hepatitis B and hepatitis C coinfection, 9.6%;
• Ongoing symptoms similar to glandular fever (mononucleosis), 5.3%;
• Unexplained swollen lymph nodes (lymphadenopathy), 4.4%;
• Unexplained, ongoing low white blood cell counts (leukocytopenia) or low platelet counts (thrombocytopenia), 4.0%;
• Hospitalization with pneumonia, 3.2%;
• Unexplained peripheral neuropathy, 2.4%;
• Hepatitis C (without hepatitis B), 2.3%;
• Rash on the face, scalp, or chest (seborrheic dermatitis), 2.0%;
• Hepatitis B (without hepatitis C), 1.2%;
• Abnormal changes in cervical cells (CIN II) or cervical cancer, 1.0%;
• Cancer of the lymph nodes (lymphoma), 0.7%.

Perhaps surprisingly, no cases of undiagnosed HIV were picked up in people with anal cancer or lung cancer. But this may also reflect limited engagement with HIV testing by clinicians in these specialties -- only 53 and 144 people who had these conditions were tested.

The large variations in the number of people testing across medical conditions and between European regions suggest that implementation of the "routine offer" may have been patchy, even if the researchers did not present data on this. Previous research has highlighted numerous challenges to the implementation of HIV testing by non-HIV specialists. While patients generally agree to be tested, clinicians may have other priorities or feel ill-equipped to deal with the topic of HIV.

In a related project (presented in 2013), the same group of researchers collected audit data from across Europe to assess day-to-day clinical practice regarding HIV testing in relation to 6 indicator conditions in which the link with HIV is widely accepted. These were tuberculosis, non-Hodgkin's lymphoma, anal cancer, cervical cancer, viral hepatitis, and oral thrush. Overall, 72% of patients who had one of these conditions actually received an HIV test, but this varied considerably by medical condition. Whereas 97% of those with hepatitis received a test, 31% of people with cancer did. Performance appeared to be better in participating clinics in Eastern Europe than in Western Europe.

Unsupportive Guidelines

One of the problems in getting people with indicator conditions tested for HIV is that guidelines for the health condition often make no mention of HIV testing. The scale of the problem in the UK was assessed in another study presented at the BHIVA conference.

The UK’s HIV testing guidelines -- prepared by HIV specialists -- were published in 2008 and recommended HIV testing for all patients with 11 AIDS-defining conditions and 37 clinical indicator diseases. But as clinicians managing these diseases may not be aware of HIV guidelines, it is important that guidance issued by the National Institute for Health and Care Excellence (NICE) and by specialist societies such as the British Society of Gastroenterology also recommend HIV testing.

The researchers identified 60 clinical guidelines, all published since 2008. Less than half (26) made any mention of HIV testing, and only a third (20) actually recommended it. While only 6 recent guidelines on AIDS-defining conditions were identified, just 3 of them recommended HIV testing. The authors recommend that HIV clinicians and specialist societies should engage with guideline development groups, including NICE, to make the case for HIV testing to be included in future guidelines. The new data from the Europe-wide study may help them do so.

Making Testing the Default Option

One of the highest rates of undiagnosed HIV (5.3%) in the European study was for individuals with symptoms that could be glandular fever or mononucleosis. These include tiredness, fever, sore throat, skin rash, and swollen lymph nodes. The same symptoms frequently occur during acute HIV infection as people seroconvert.

The BHIVA conference heard that a technically straightforward automated system in primary care clinics can dramatically improve HIV testing rates in people with suspected glandular fever. The program was implemented through the ViaPath laboratory at St. Thomas' Hospital, which serves many general practices in an area of London with a very high HIV prevalence.

GPs can order glandular fever screens through a paper form or electronically. Previously, samples were tested for Epstein-Barr virus (the cause of glandular fever), cytomegalovirus, and toxoplasmosis. Test results came back with a printed suggestion of recommending an HIV test, but only a third of patients were tested.

The system for electronically requesting a glandular fever screen was improved so that an HIV test would be added, unless the doctor or patient specifically refused it. The result was that 68% of patients were tested for HIV and 1% of those tested were diagnosed with HIV.

Nonetheless, there remains great variation between different primary care clinics in terms of the proportion who turn down the test, suggesting that some doctors remain uncomfortable with the topic. 

5/1/15

References

M Rayment, G Kutsyna, A Mocroft, et al. The effectiveness of indicator condition based HIV testing across Europe: results from HIDES-2, a prospective multi-centre study. 21st Annual Conference of the British HIV Association (BHIVA). Brighton, April 21-24, 2015. Abstract O1(presentation slides available here).

A Stockdale, L Byrne, H Curtis, et al. Do UK specialty guidelines recommend testing for HIV indicator diseases? 21st Annual Conference of the British HIV Association (BHIVA). Brighton, April 21-24, 2015. Abstract P114.

S Douthwaite, S O'Shea, S Palmer, et al. London initiative for glandular fever HIV testing for diagnosis of primary HIV infection: Initial results.21st Annual Conference of the British HIV Association (BHIVA). Brighton, April 21-24, 2015. Abstract P109.